comparemela.com

Latest Breaking News On - Bruno sangro - Page 1 : comparemela.com

Systemic Treatment Plus Embolization Reduces Risk of Death in Patients With Hepatocellular Carcinoma

Compared to embolization alone, the systemic treatment combination nearly doubled progression-free survival among patients with unresectable liver cancer.

United statesSan franciscoSusan galbraithDurvalumab imfinziBruno sangroUniversidad de navarra

Durvalumab Treatment Regimen Reduces Risk of Disease Progression, Death in Patients With HCC

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

San franciscoUnited statesBruno sangroSusan galbraithLiver unitUniversidad de navarra

AstraZeneca s Imfinzi combination shows promise in phase 3 liver cancer study

AstraZeneca s Imfinzi combination shows promise in phase 3 liver cancer study
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesSusan galbraithBruno sangroGenentech avastinAmerican societyUniversidad de navarra

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs TACE in liver cancer eligible for embolization

EMERALD-1 is first global Phase III trial to show improved clinical outcome for systemic therapy in combination with TACE in this setting .

United statesUnited kingdomSan franciscoSouth koreaSusan galbraithBruno sangroDaiichi sankyoNational cancer instituteWorld health organizationBiosciences incMerck co incLiver unitUniversidad de navarraExecutive vice presidentResponse rateBlinded independent central review

AstraZeneca: encouraging results in liver cancer -January 19, 2024 at 11:22 am EST

AstraZeneca reports that positive results from a phase III trial showed that Imfinzi combined with TACE and bevacizumab demonstrated a statistically and clinically significant improvement in.

United statesSan franciscoBruno sangroAmerican society of clinical oncologyLiver unitUniversidad de navarraAmerican societyClinical oncologyCancer symposium

vimarsana © 2020. All Rights Reserved.